A double‐blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy

The purpose of this study was to define an optimal administration schedule of granisetron for patients receiving moderately emetogenic chemotherapy by comparing the antiemetic efficacy and safety of 2 mg of the drug administered orally.

[1]  G. Sanger,et al.  Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). , 1989, European journal of pharmacology.

[2]  B. Chevallier.  The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group. , 1993, British Journal of Cancer.

[3]  R. Palmer,et al.  Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. McArdle,et al.  Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. , 1979, British medical journal.

[5]  D. Gandara,et al.  Serotonin antagonists: a new class of antiemetic agents. , 1991, Journal of the National Cancer Institute.

[6]  M. Spielmann,et al.  Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. , 1995, Clinical therapeutics.

[7]  D. Serraino,et al.  Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Barni,et al.  The biological significance of soluble interleukin-2 receptors in solid tumors. , 1990, European journal of cancer.

[9]  P. Hesketh,et al.  Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. , 1996, The cancer journal from Scientific American.

[10]  D. Gandara,et al.  Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Kataja,et al.  5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study. , 1993, European journal of cancer.

[12]  M. Marty.  A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis , 1990 .

[13]  G. Sanger,et al.  Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonism , 1986, British journal of pharmacology.

[14]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[15]  B. Chevallier.  Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study , 1990 .

[16]  S. Dilly,et al.  A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference , 1994 .

[17]  M. Kris,et al.  Methodology in anti-emetic trials. , 1991, European journal of cancer.

[18]  P. Andrews.  The pharmacologic profile of granisetron (Kytril). , 1994, Seminars in oncology.

[19]  L. Goedhals,et al.  Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  K. Jenns,et al.  Importance of nausea , 1994, Cancer nursing.

[21]  G. Blijham.  Does granisetron remain effective over multiple cycles , 1992 .

[22]  G. Sledge,et al.  Phase III double‐blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple‐day cisplatin‐based chemotherapy , 1992, Cancer.

[23]  C. Seynaeve,et al.  Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. , 1990, Annals of internal medicine.

[24]  V. Diehl,et al.  Efficacy and safety of antiemetics. , 1994, Cancer treatment reviews.

[25]  M. Tonato,et al.  Methodology of antiemetic trials: a review. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  D. Cupissol,et al.  The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. , 1990, European journal of cancer.

[27]  D. Amadori,et al.  Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Tonato,et al.  Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. , 1985, Cancer treatment reports.

[29]  L. L. Stevenson,et al.  Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I. Smith.  A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group. , 1990, European Journal of Cancer.

[31]  M. Kris,et al.  The management of chemotherapy-induced nausea and vomiting. , 1987, The Medical clinics of North America.

[32]  M. Soukop.  A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group. , 1990, European journal of cancer.

[33]  P. Ruff,et al.  Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study , 1994 .

[34]  D. Kamanabrou.  Intravenous granisetron--establishing the optimal dose. The Granisetron Study Group. , 1992, European journal of cancer.

[35]  F. di Costanzo,et al.  Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Grochow,et al.  The course of nausea and vomiting after high-dose cyclophosphamide. , 1982, Cancer treatment reports.

[37]  M. Tonato,et al.  Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Almenarez,et al.  The natural course of emesis after carboplatin treatment. , 1990, Acta oncologica.

[39]  R. Joss,et al.  The symptomatic control of cytostatic drug-induced emesis. A recent history and review. , 1990, European journal of cancer.

[40]  A. Rivière.  Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group. , 1994, British Journal of Cancer.

[41]  J. Droz,et al.  Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. , 1990, The New England journal of medicine.